$37.01
1.31% yesterday
Nasdaq, Dec 24, 04:17 pm CET
ISIN
US9183851057
Symbol
VTVT

vTv Therapeutics, Inc. Class A Stock price

$37.01
+7.15 23.95% 1M
+21.21 134.24% 6M
+23.20 168.02% YTD
+23.14 166.83% 1Y
+9.87 36.35% 3Y
-44.99 54.87% 5Y
-253.79 87.27% 10Y
-398.59 91.50% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
-0.49 1.31%
ISIN
US9183851057
Symbol
VTVT
Industry

Key metrics

Basic
Market capitalization
-
Enterprise Value
-
Net debt
positive
Cash
$98.5m
Shares outstanding
3.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
31.9%
Return on Equity
-151.3%
ROCE
-33.4%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$20.0k | $0.0
EBITDA
$-29.8m | -
EBIT
$-29.8m | $-36.2m
Net Income
$-23.5m | $-16.3m
Free Cash Flow
$-20.8m
Growth (TTM | estimate)
Revenue
-98.0% | -100.0%
EBITDA
-24.6% | -
EBIT
-24.3% | -49.6%
Net Income
-28.2% | 12.0%
Free Cash Flow
10.9%
Margin (TTM | estimate)
Gross
-
EBITDA
-175,170.6% | -
EBIT
-175,382.4%
Net
-138,058.8% | -
Free Cash Flow
-122,523.5%
More
EPS
$-2.9
FCF per Share
$-5.3
Short interest
0.8%
Employees
23
Rev per Employee
$40.0k
Show more

Is vTv Therapeutics, Inc. Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

vTv Therapeutics, Inc. Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a vTv Therapeutics, Inc. Class A forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a vTv Therapeutics, Inc. Class A forecast:

Buy
89%
Hold
11%

Financial data from vTv Therapeutics, Inc. Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
0.02 0.02
98% 98%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 14 14
1% 1%
68,250%
- Research and Development Expense 16 16
41% 41%
80,950%
-30 -30
25% 25%
-148,900%
- Depreciation and Amortization 0.04 0.04
56% 56%
200%
EBIT (Operating Income) EBIT -30 -30
24% 24%
-149,075%
Net Profit -23 -23
28% 28%
-117,350%

In millions USD.

Don't miss a Thing! We will send you all news about vTv Therapeutics, Inc. Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

vTv Therapeutics, Inc. Class A Stock News

Neutral
GlobeNewsWire
7 days ago
Trial to assess cadisegliatin as potential adjunctive therapy to insulin in patients with T2D Trial to assess cadisegliatin as potential adjunctive therapy to insulin in patients with T2D
Neutral
GlobeNewsWire
about 2 months ago
Topline Phase 3 CATT1 data for cadisegliatin in type 1 diabetes expected second half 2026  $80 million private placement strengthens balance sheet and supports Phase 3 CATT1 completion Announced issuance of new U.S. patent covering crystalline salts and co-crystals forms of cadisegliatin with exclusivity expected out to 2041 HIGH POINT, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics I...
Neutral
GlobeNewsWire
3 months ago
Board to offer guidance on clinical development of cadisegliatin for type 1 diabetes as company has initiated Phase 3 trials Board to offer guidance on clinical development of cadisegliatin for type 1 diabetes as company has initiated Phase 3 trials
More vTv Therapeutics, Inc. Class A News

Company Profile

vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC.

Head office United States
CEO Paul Sekhri
Employees 23
Founded 2015
Website vtvtherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today